Nurami Medical, a trailblazer in the development of advanced solutions for soft tissue repair, announced today a significant milestone in its journey towards transforming the medical landscape. The company has been awarded a €2.5 million grant from the European Innovation Council (EIC) Horizon Accelerator program, coupled with additional equity investment. This funding underscores Nurami’s pioneering technology and its potential to revolutionize the field of soft tissue repair.
Already making waves with its inaugural product, ArtiFascia®, a cutting-edge dura repair graft currently available in the US and awaiting CE approval, Nurami is poised to expand its impact. The EIC funding will primarily fuel the advancement of its second product, currently in pivotal pre-clinical trials.
Chosen amidst stiff competition through a rigorous evaluation process, Nurami stands out for its innovative approach, leveraging electrospun polymers and smart materials. This recognition from the EIC serves as a robust validation of Nurami’s technological prowess and its compelling value proposition in enhancing patient outcomes through advanced surgical solutions.
Editorial Opinion:
Nurami Medical’s achievement of securing the €2.5 million EIC grant not only highlights its technological innovation but also underscores its potential to lead the future of soft tissue repair. With a strong foundation built on nanofiber expertise and biomaterial advancements, co-founders Dr. Amir Bahar and Nora Nseir Manassa have positioned Nurami as a frontrunner in the industry. The company’s commitment to improving recovery in soft tissue surgeries aligns with global healthcare needs, promising significant advancements in patient care and surgical outcomes.
Nora Nseir Manassa, Nurami’s CTO, Co-CEO, and founder, previously emphasized, “Nurami is involved in ongoing efforts for the development of additional solutions for soft tissue repair and healing, for additional clinical indications, based on our technological platform which incorporates novel materials and unique manufacturing processes.”
For further inquiries or corrections, please contact editor@thetimesmag.com.
